000182679 001__ 182679
000182679 005__ 20240229145727.0
000182679 0247_ $$2doi$$a10.1016/j.jtho.2022.10.020
000182679 0247_ $$2pmid$$apmid:36396063
000182679 0247_ $$2ISSN$$a1556-0864
000182679 0247_ $$2ISSN$$a1556-1380
000182679 0247_ $$2altmetric$$aaltmetric:138610772
000182679 037__ $$aDKFZ-2022-02847
000182679 041__ $$aEnglish
000182679 082__ $$a610
000182679 1001_ $$aGarcía-Pardo, M.$$b0
000182679 245__ $$aRespiratory and cardiometabolic comorbidities and Stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO).
000182679 260__ $$aAmsterdam$$bElsevier$$c2023
000182679 3367_ $$2DRIVER$$aarticle
000182679 3367_ $$2DataCite$$aOutput Types/Journal article
000182679 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1677577088_27831
000182679 3367_ $$2BibTeX$$aARTICLE
000182679 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182679 3367_ $$00$$2EndNote$$aJournal Article
000182679 500__ $$aVolume 18, Issue 3, March 2023, Pages 313-323
000182679 520__ $$aWe explored the association of respiratory and cardiometabolic comorbidities with NSCLC overall survival (OS) and lung cancer specific survival (LCSS), by stage, in a large, multi-continent NSCLC pooled dataset.Based on patients pooled from 11 ILCCO studies with available respiratory and cardiometabolic comorbidity data, adjusted Hazard Ratios (aHR) were estimated using Cox models for OS. LCSS was evaluated using competing risk Grey and Fine models and cumulative incidence functions. Logistic regression (adjusted odds ratio, aOR) was applied to assess factors associated with surgical resection.OS analyses utilized NSCLC patients with respiratory health or cardiometabolic health data (N=16,354); a subset (N=11,614) contributed to LCSS analyses. In stage I-IIIA NSCLC, patients with respiratory comorbidities had worse LCCS (Stage IA aHR 1.51, CI 1.17-1.95; Stage IB-IIIA aHR 1.20, CI 1.06-1.036). In contrast, stage I-IIIA patients with cardiometabolic comorbidities had a higher risk of death from competing (non-NSCLC) causes (Stage IA aHR 1.34, CI 1.12-1.69). The presence of respiratory comorbidities was inversely associated with having surgical resection (Stage IA aOR 0.54 CI 0.35-0.83; Stage IB-IIIA aOR 0.57, CI 0.46-0.70).The presence of either cardiometabolic or respiratory comorbidities is associated with worse OS in Stage I-III NSCLC. Patients with respiratory comorbidities were less likely to undergo surgery and had worse LCSS, while patients with cardiometabolic comorbidities had a higher risk of death from competing causes. As more treatments options for Stage I-III NSCLC are introduced into practice, accounting for cardiometabolic and respiratory comorbidities becomes essential in trial interpretation and clinical management.
000182679 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000182679 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182679 650_7 $$2Other$$aCOPD
000182679 650_7 $$2Other$$aComorbidity
000182679 650_7 $$2Other$$aNSCLC
000182679 7001_ $$aChang, A.$$b1
000182679 7001_ $$aSchmid, S.$$b2
000182679 7001_ $$aDong, M.$$b3
000182679 7001_ $$aBrown, M. C.$$b4
000182679 7001_ $$aChristiani, D.$$b5
000182679 7001_ $$aTindel, H. A.$$b6
000182679 7001_ $$aBrennan, P.$$b7
000182679 7001_ $$aChen, C.$$b8
000182679 7001_ $$aZhang, J.$$b9
000182679 7001_ $$aRyan, B. M.$$b10
000182679 7001_ $$aZaridze, D.$$b11
000182679 7001_ $$aSchabath, M. B.$$b12
000182679 7001_ $$aLeal, L. F.$$b13
000182679 7001_ $$aReis, R. M.$$b14
000182679 7001_ $$aTardon, A.$$b15
000182679 7001_ $$aFernández-Tardon, G.$$b16
000182679 7001_ $$aShete, S. S.$$b17
000182679 7001_ $$aAndrew, A.$$b18
000182679 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, H.$$b19$$udkfz
000182679 7001_ $$aXu, W.$$b20
000182679 7001_ $$aHung, R. J.$$b21
000182679 7001_ $$aLiu, G.$$b22
000182679 773__ $$0PERI:(DE-600)2223437-8$$a10.1016/j.jtho.2022.10.020$$gp. S1556086422019037$$n3$$p313-323$$tJournal of thoracic oncology$$v18$$x1556-0864$$y2023
000182679 909CO $$ooai:inrepo02.dkfz.de:182679$$pVDB
000182679 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000182679 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000182679 9141_ $$y2022
000182679 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000182679 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000182679 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2023-10-25$$wger
000182679 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000182679 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000182679 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000182679 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000182679 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000182679 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000182679 980__ $$ajournal
000182679 980__ $$aVDB
000182679 980__ $$aI:(DE-He78)C070-20160331
000182679 980__ $$aUNRESTRICTED